$3 B

AGIO Mkt cap, 14-Dec-2018

$15.2 M

Agios Pharmaceuticals Revenue Q3, 2018
Agios Pharmaceuticals Gross profit (Q3, 2018)14.5 M
Agios Pharmaceuticals Gross profit margin (Q3, 2018), %95.4%
Agios Pharmaceuticals Net income (Q3, 2018)-94.7 M
Agios Pharmaceuticals EBIT (Q3, 2018)-99.2 M
Agios Pharmaceuticals Cash, 30-Sep-2018156.5 M

Agios Pharmaceuticals Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.5m65.4m59.1m69.9m43.0m

Revenue growth, %

156%(10%)18%

R&D expense

54.5m141.8m220.2m292.7m

General and administrative expense

9.9m36.0m50.7m71.1m

Operating expense total

64.4m177.8m270.9m363.8m

EBIT

(38.9m)(54.1m)(118.7m)(201.0m)(320.8m)

EBIT margin, %

(152%)(83%)(201%)(288%)(746%)

Interest income

55.0k203.0k968.0k2.5m6.1m

Pre tax profit

(117.7m)(198.5m)

Income tax expense

579.0k(426.0k)(426.0k)

Net Income

(39.4m)(53.5m)(117.7m)(198.5m)(314.7m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

6.3m8.4m34.2m13.2m5.5m31.3m7.0m9.0m10.5m11.4m8.8m49.2m15.2m

Cost of goods sold

695.0k

Gross profit

14.5m

Gross profit Margin, %

95%

R&D expense

14.8m17.4m22.6m25.5m32.4m36.4m36.0m44.0m50.8m60.6m62.7m79.8m72.9m78.2m165.0m82.6m

General and administrative expense

2.5m3.3m4.2m5.2m7.0m8.9m9.9m10.8m12.6m11.9m14.8m16.1m17.5m24.6m51.2m31.1m

Operating expense total

17.3m20.7m26.7m30.7m39.4m45.4m46.0m54.9m63.4m72.5m77.6m95.9m90.4m102.8m216.1m114.4m

EBIT

(11.1m)(12.3m)(18.3m)3.2m(5.2m)(32.1m)(40.5m)(23.6m)(56.5m)(63.5m)(67.0m)(84.6m)(79.0m)(94.0m)(167.0m)(99.2m)

EBIT margin, %

(177%)(218%)(15%)(243%)(739%)(75%)(809%)(707%)(638%)(696%)(1073%)(340%)(652%)

Interest income

13.0k36.0k34.0k48.0k238.0k236.0k218.0k396.0k517.0k678.0k881.0k1.5m1.9m3.2m7.4m4.5m

Pre tax profit

(12.2m)(18.3m)3.3m

Income tax expense

121.0k(448.0k)

Net Income

(11.2m)(12.2m)(18.3m)3.7m(5.0m)(31.9m)(40.3m)(23.2m)(56.0m)(62.8m)(66.2m)(83.1m)(77.1m)(90.8m)(159.6m)(94.7m)

Agios Pharmaceuticals Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6m14.0m71.8m160.8m102.7m

Accounts Receivable

2.3m600.0k

Inventories

2.5m4.8m8.7m10.3m

Current Assets

169.7m359.5m337.3m559.9m445.3m

PP&E

3.8m6.4m23.2m25.3m24.4m

Total Assets

201.2m491.9m420.1m619.1m614.4m

Accounts Payable

3.7m11.1m14.7m17.1m22.8m

Short-term debt

Current Liabilities

36.9m61.1m52.9m88.4m94.9m

Long-term debt

Total Debt

Total Liabilities

238.9m

Preferred Stock

Additional Paid-in Capital

244.9m591.3m630.1m842.0m1.2b

Retained Earnings

(113.4m)(166.9m)(284.7m)(483.2m)(798.1m)

Total Equity

131.5m424.4m345.1m358.6m375.5m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x1.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

106.0m32.8m108.2m70.0m35.3m72.5m80.0m39.0m234.0m285.5m200.3m138.7m132.7m364.5m210.3m156.5m

Accounts Receivable

2.6m

Inventories

863.0k

Current Assets

198.8m172.4m245.2m247.6m364.1m390.2m371.7m329.5m484.2m600.9m506.9m604.7m528.3m803.0m753.8m695.5m

PP&E

3.6m3.5m3.2m3.7m14.3m19.3m21.1m23.0m25.1m26.3m24.1m24.8m24.0m23.7m24.1m24.6m

Total Assets

219.1m181.9m272.0m269.6m474.3m474.4m449.1m396.1m557.6m672.0m557.3m760.6m687.2m1.0b998.2m929.1m

Accounts Payable

2.1m4.4m5.4m6.2m12.6m8.9m9.0m13.7m18.4m15.4m16.2m23.4m17.9m17.9m17.3m16.6m

Current Liabilities

37.4m34.1m44.6m35.1m36.4m45.2m49.8m45.1m67.3m78.0m82.4m93.6m88.1m74.7m84.9m84.7m

Total Liabilities

251.6m237.4m174.5m175.1m168.9m

Additional Paid-in Capital

243.6m247.0m344.5m347.9m598.5m607.7m619.5m640.1m652.6m828.0m857.1m1.1b1.2b1.7b1.7b1.8b

Retained Earnings

(101.1m)(125.7m)(144.0m)(140.3m)(171.9m)(203.8m)(244.1m)(307.9m)(363.8m)(426.7m)(549.6m)(632.6m)(709.8m)(849.4m)(918.2m)(1.0b)

Total Equity

142.6m121.3m200.5m207.7m426.8m404.2m375.7m332.4m289.1m401.4m307.4m509.0m449.8m865.6m823.1m760.2m

Financial Leverage

1.5 x1.5 x1.4 x1.3 x1.1 x1.2 x1.2 x1.2 x1.9 x1.7 x1.8 x1.5 x1.5 x1.2 x1.2 x1.2 x

Agios Pharmaceuticals Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.4m)(53.5m)(117.7m)(198.5m)(314.7m)

Depreciation and Amortization

1.4m1.4m3.3m5.7m6.4m

Accounts Receivable

(2.3m)(1.0m)

Inventories

Accounts Payable

30.0k7.6m4.2m3.5m5.3m

Cash From Operating Activities

(56.4m)(59.4m)(76.9m)38.6m(285.2m)

Purchases of PP&E

(1.3m)(2.2m)(20.2m)(9.9m)(4.6m)

Cash From Investing Activities

(87.2m)(333.3m)128.3m(119.3m)(57.9m)

Cash From Financing Activities

123.9m335.2m6.4m169.8m285.1m

Income Taxes Paid

6.0m6.0m6.0m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(11.2m)(12.2m)(18.3m)(26.8m)(5.0m)(36.9m)(77.1m)(23.2m)(79.2m)(142.0m)(66.2m)(149.2m)(226.4m)(90.8m)(159.6m)(254.2m)

Depreciation and Amortization

332.0k1.0m1.2m2.2m1.2m2.6m4.0m1.6m3.2m4.8m1.7m3.5m5.3m

Accounts Receivable

(2.9m)(659.0k)(2.6m)

Inventories

(863.0k)

Accounts Payable

720.0k5.4m2.4m12.6m(1.2m)(1.3m)(293.0k)3.8m1.7m(994.0k)4.9m742.0k(4.5m)(6.2m)(5.8m)

Cash From Operating Activities

(27.0m)(51.6m)(21.6m)(46.4m)(19.0m)138.8m89.8m(74.1m)(133.1m)(210.8m)(99.0m)(166.4m)(230.2m)

Purchases of PP&E

(13.0k)(727.0k)(14.7m)(18.0m)(2.5m)(5.3m)(8.7m)(293.0k)(1.3m)(3.3m)(1.4m)(2.8m)(5.9m)

Cash From Investing Activities

(12.3m)(46.0m)77.2m107.4m(14.8m)20.9m(41.8m)109.6m(166.2m)(99.8m)(167.5m)(263.8m)(261.0m)

Cash From Financing Activities

582.0k96.1m2.9m5.1m1.1m2.6m165.8m4.0m277.2m282.5m528.3m537.8m545.0m

Income Taxes Paid

6.0m6.0m6.0m6.0m

Agios Pharmaceuticals Ratios

USDY, 2018

Financial Leverage

1.2 x
Report incorrect company information

Agios Pharmaceuticals Employee Rating

3.731 votes
Culture & Values
4.1
Work/Life Balance
3.7
Senior Management
3.9
Salary & Benefits
4.2
Career Opportunities
4.1
Source